INTRODUCTION
============

Hearing loss is one of the most common disorders of sensorineural function and it affects at least 30% of the population at some time in their lives. Congenital deafness is one of the common birth defects in human. Approximately 1 out of every 700-1,000 neonates was born with congenital deafness. In terms of the etiology of childhood hearing loss, half of the cases have a genetic cause and 70% of all cases of genetic hearing impairment are nonsyndromal. The most common known cause is autosomal recessive nonsyndromic hearing loss (NSHL). In the Chinese population, studies have shown that a large proportion of nonsyndromic forms of hearing loss is caused by a limited number of genes with recurrent mutations, such as gap junction beta-2 protein (*GJB2*), gap junction beta-3 protein (*GJB3*), solute carrier family 26 member 4 (*SLC26A4*), and mitochondrial DNA (mtDNA) 12S rRNA \[[@B1]\], which would facilitate clinical testing. *GJB2* gene mutation can cause autosomal dominant nonsyndromic deafness (DFNA3A) and autosomal recessive nonsyndromic hearing loss (DFNB1A). Forty to sixty percent of patients with sensorineural deafness in early childhood are caused by the *GJB2* type of mutation \[[@B2]\], which are characterized as congenital sensorineural hearing loss, noncongenital prelingual deafness and postlingual deafness, with onset age from 6-8 months to 20 years \[[@B3]\]. Carrier frequency of *GJB2* gene mutations c.235delC is the most common type of mutational spot in the Chinese population, which can cause severe or profound hearing loss by its homozygous mutations. A mutation in the *SLC26A4* gene is the second major contributor to genetic hearing loss, after *GJB2* mutations, and is responsible for DFNB4 and enlarged vestibular aqueduct (EVA). Its most common mutational sites is IVS7-2A\>G, followed by p.H723R \[[@B4]\]. *GJB3* is one of the members of gap junction proteins. *GJB3* may cause DFNA2B and DFNB91. m.1494C\>T and m.1555A\>G in mitochondrial 12S rRNA have close relationship with aminoglycoside antibiotic induced deafness (AAID), both incidences of which increase with age \[[@B5]\].

The incidence of neonates with permanent hearing loss has reached the 1.33-1.86 per thousand, with the implementation of the newborn hearing screening (NHS) and the project for early diagnosis and early intervention hearing loss. The incidence of permanent hearing loss in children continues to increase as the age became older \[[@B6]\]. The proportion of children with hearing loss is up to 2.7 per thousand in children younger than 5 years old, which reaches 3.5 per thousand in adolescents. The changes of incidence of hearing loss occur closely related to deafness induced genetic factors. As NHS was carried out, the assessment and reflection on its effects performed simultaneously. More and more inherent limitations were noticed. Firstly, permanent hearing loss can be detected easily by NHS, whereas the mild hearing loss cannot \[[@B7]\]; secondly, late-onset deafness or progressive deafness cannot be detected by NHS, since these neonates were born with normal hearing. Some diseases, such as cytomegalovirus infection, Pendred syndrome, nonsyndrome with autosomal recessive inheritance of EVA as well as mitochondria gene (mtDNA) 12S rRNA m.1555A\>G and m.1494C\>T mutations, may result in late-onset hearing with normal hearing at birth. Previous studies have shown that it is crucial for a child that hearing impairment in early childhood was identified before he/she is less than six months, and thus early intervention could be performed. On the other hand, early detection of infant hearing loss has far-reaching significance for later communication, cognition, mental health, career planning and so on \[[@B8]\]. The aim of current study is to know, whether neonatal screening for deafness through cord blood can make up for the inadequacy of the NHS, the common mutational types in neonatal deafness gene in the population of the local, to develop considerable screening program suitable for this region.

MATERIALS AND METHODS
=====================

Subjects
--------

Six hundred and forty-six newborns were recruited in current study. All subjects were born in the obstetrical department at Handan Centre Hospital between November 2010 and October 2011.

This study was conducted in accordance with the declaration of Helsinki. This study was conducted with approval from the Ethics Committee of Handan Centre Hospital. Written informed consent was obtained from all participants\' guardians.

Neonatal hearing screening
--------------------------

All the subjects were examined bedside in maternity ward by transient evoked otoacoustic emission. Hearing screening was performed in the maternity ward and the newborns were tested under quiet natural sleeping conditions using ambient noise \<30 dB. Every infant was examined at the third day after birth with Accuscreen-otoacoustic emission instrument (MADSEN AccuScreen, GN Otometrics, Taastrup, Denmark). The left and right ear was randomly examined. The Otoacoustic emission instrument displays \"PASS\" or \"REFER\" to show normal or not. Those infants with Monaural or binaural fails will be followed up and come back to hospital for recheck in 42 days after birth. Those babies with two times of \"REFER\" need to further audiological examination and identification of permanent hearing loss (<http://www.cdc.gov/ncbddd/ehdi/ehdi.htm>).

Gene screening
--------------

Up to 2-mL cord blood from umbilical vein were collected into vacuum blood tube with ethylenediaminetetraacetic acid anticoagulant by the obstetrician before the delivery of the placenta. The blood cells were preserved at -80℃ after separation for later gene screening for deafness. Genomic DNA of all subjects was extracted by using AxyPrep genomic DNA extraction Kit (Axygen Biotechnology Co., Silicon Valley, CA, USA), following the kit instructions in the process of extraction.

MassArray system (Sequenom Inc., San Diego, CA, USA) screening for deafness gene array technology platform was used in current study, which is based on matrix assisted laser desorption ionization time of flight mass spectrometry, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) technology ([Fig. 1](#F1){ref-type="fig"}). Assay Designer package (Sequenom Inc.) was used to design polymerase chain reaction (PCR) primers and single base extension primers. 20 sites can be tested simultaneously in one well ([Table 1](#T1){ref-type="table"}).

PCR amplification of the MassArray system and single base extension were performed strictly accordance with the product instructions. After the multiplex PCR reaction, extra nucleotides were digested by shrimp alkaline phosphatase, and then extended by single base primer. The products were spotted in 384 holes on genotyping chip, and then were analyzed with MALDI-TOF-MS. Final results were read by the MassARRAY RT real-time software systems. Genotype analysis was completed by the MassARRAY Typer software.

3730xl DNA analyzer (Applied Biosystems Inc., Carlsbad, CA, USA) was used for sequencing. The m.1494C\>T and m.1555A\>G mutational sites in mtDNA 12Sr RNA were screened by using direct sequencing screening, with the primers designed by the online software Primer 3 (<http://biotools.umassmed.edu/bioapps/primer3_www.cgi>). Forward primer sequences: 5\'-CAACCTCACCACCTCTTGCT-3\'; reverse primer sequences: 5\'-GTAAGGTGGAGTGGGTTTGG-3\'. PCR reaction conditions: prede-generated at 94℃ for 30 seconds; annealed at 60℃ for 30 seconds, and 72℃ extracted for 30 seconds, 35 loops; after that, extended at 72℃ for 5 minutes, 1.5% agarose gel electrophoresis to observe the PCR products. DNA mutation-positive samples were reverse sequenced for validation.

RESULTS
=======

Newborn hearing screening
-------------------------

Six hundred and forty-six newborns were examined by traditional hearing screening. Among them, 103 cases did not pass the initial screening. In the secondary screening at the 42nd day after birth, a total of 12 cases failed ([Table 2](#T2){ref-type="table"}). Five cases (0.7%) failed in unilateral hearing examination. Six cases failed in bilateral hearing screening. A total of fail rate of NHS was 1.7%.

Deafness gene screening
-----------------------

Among the 11 cases who failed the NHS, two cases carrying p.R143W homozygous mutation, one case carrying c.235delC single heterozygous mutations in *GJB2* gene (suspicious pathogenic mutations), and one case carrying p.R180X pathogenic homozygous mutation in gene *GJB3*. No hot spot mutation was found in the other seven cases. After full-length sequencing on above four most common deafness genes (*GJB2*, *GJB3*, *SLC26A4*, and mtDNA 12S rRNA), one cases was found carrying c.299-300delAT single heterozygous mutation in *GJB2* gene, another one cases carrying p.V37I pathogenic homozygous mutation. No mutation was found in above four common deafness genes in the remaining 5 cases (detailed gene type; [Table 3](#T3){ref-type="table"}).

Among the 634 newborns who passed the NHS, many cases were found carrying deafness mutations in alleles. A total of 25 cases (3.9%) were found carrying pathogenic mutations ([Table 4](#T4){ref-type="table"}). Three hundred and thirty-seven cases (53.2%) were found carrying suspected pathogenic mutations ([Table 5](#T5){ref-type="table"}). Twelve out of 25 pathogenic mutations occurred in *GJB2* allele. By sequencing the coding regions of the *GJB2* gene, one p.V37I heterozygous mutation was found in one case, and two polymorphic sites p.V27I was found in two cases, no mutation was found in other 10 cases. High rates of possible pathogenic mutations p.E114G in *GJB2* gene were found in 292 cases (45.2%), including 54 homozygous mutations and 238 heterozygous mutations. Since all carriers passed the examination of the NHS, the mutation p.E114G is supposed to be polymorphic sites in this region. On gene *GJB3*, possible pathogenic heterozygous mutation p.V84I was found in only one case, simultaneously with mitochondrial 827A\>G mutation. On gene *SLC26A4*, single heterozygous mutation IVS7-2A\>G was found in 8 cases and p.R409H mutation was found in one case. mtDNA 12S rRNA mutations were found in 48 cases, including 21 cases with m.827A\>G mutation, 23 cases with m.1005T\>C mutation, two cases with m.1494T\>C mutation, and two cases with m.1555A\>G mutation, all of which were homoplasmic mutations.

DISCUSSION
==========

Early diagnosis of neonatal hearing impairment plays a very important role in their early treatment or use of hearing aids, and for a better language development. Current paid a close attention to the common deafness genes in neonates by using the MassArray platform and Sanger sequencing. By traditional NHS, hearing impairment can be found in 1.7% of the subjects, whereas up to 4.5% of the subjects were detected carrying pathogenic deafness mutations by gene screening in current study. By sequencing the four common deafness genes of neonates who failed the NHS, the rate of pathogenic rate increased to 4.7% of the subjects who failed NHS. Audiology diagnosis for those who failed NHS could not be made until the neonate is three months old under current diagnostic mode, while gene screening method provides us the accurate information of deafness gene mutations shortly after birth to allow the intervention and treatment made much earlier.

Mutations of *GJB2* gene are considered to be the most common cause of sensorineural hearing loss by far. From [Table 3](#T3){ref-type="table"}, among the 11 neonates who failed the NHS, two types of homozygous mutations were detected in three neonates including p.R143W (NB47 and NB504, 16.7%) and p.V37I (NB10, 8.3%), one single heterozygous mutation c.235delC was detected in one case (NB106). As we have known, homozygous mutations p.R143W in *GJB2* gene can cause recessive nonsyndromic sensorineural deafness \[[@B9]\]. High rate of p.R143W mutation in *GJB2* gene (0.3%) in Jinan area indicated that it might be one of the major reasons for neonatal hearing loss in this region. On the other hand, c.235delC single heterozygous mutation was found in 13 neonates. No mutation was found in encoding area by sequencing *GJB2* gene. Otherwise, there might be mutations in regulatory region in the genes sequenced or mutations in other genes related to the cause of hearing loss. Among 12 neonates who passed NHS, one neonate was found carrying complex heterozygous mutation p.V37I and c.235delC. The carriers with complex heterozygous mutation p.V37I and c.235delC might be normal without hearing impairment when they are born, whereas they often suffer mild, progressive, or asymmetry deafness later. The neonate with NB10 mutation is abnormal with hearing loss in only one ear. This patient also needs follows up, since carriers with p.V37I mutation commonly characterized by progressive deafness \[[@B10]\]. It was known that p.R180X in *GJB3* gene could cause DFNA2B. Single heterozygous mutations in NB121 could cause neonatal deafness, consistent with its dominant characteristics of the deaf. Whether if p.V84I mutation is the cause of dominant deafness is not convinced yet, although it is detected frequently in Chinese, which needs further study \[[@B11]\]. In current study, p.V84I mutation was found in only one newborn with normal NHS result.

The nine neonates with IVS7-2A\>G and p.R409H mutations in *SLC26A4* gene all passed the NHS, who might be just mutation carriers. These carriers still had the possibility of suffering from EVA and nonsyndrome DFNB4. Previous studies showed that patients with EVA and DFNB4 were commonly born with normal hearing or mild hearing impairment, although they got worse at growth stage \[[@B12]\]. From an English study enrolled with 43 cases with EVAs, biallelic gene mutations were found in 17 cases, single allele mutations were found in 16 cases \[[@B13]\]. Generally, double-allele mutations can lead to phenotypic abnormality, however, *SLC26A4* gene mutations were found in quite a few subjects with NSHL, what role does single-allele mutations play in NSHL is still a question. Some pathogenic mutations might be located in promoter region or splice site, which were not detected in this study. The current study shows carriers with single-allele gene mutation has more probability to contract EVAS \[[@B14]\]. Those nine newborns with IVS7-2A\>G and p.R409H mutations in *SLC26A4* gene should be regular followed up and avoid activity that may cause damage to the ears.

mtDNA 12S rRNA m.1494C\>T and m.1555A\>G were the most two common mutation sites associated with AAID. The detection rates of m.1555A\>G mutation (3.96%) was much higher than that of m.1494C\>T mutation (0.18%) in AAID patients \[[@B15]\]. The detection rate of m.1555A\>G in previous neonatal screening for deafness genes was 0%-0.16% \[[@B16][@B17]\]. In this study, the mutation rate for both m.1555A\>G and m.1494C\>T were 0.3%, indicated that the detection rates of these two mutations were accordant with each other. It is necessary to incorporate routine screening project. Because mitochondrial genetic are maternally inherited, four cases with positive mutations consisted of three girls and one boy. The study on AAID patients indicated that, the time of aminoglycoside drugs therapy for carriers with m.1494C\>T and m.1555A\>G mutations was related with their degree of deafness. Aminoglycosides can cause severe or profound deafness before 10 years old \[[@B18]\]. Carriers with m.1494C\>T and m.1555A\>G mutations might contract late-onset hearing loss with morphological features even without exposure to aminoglycoside antibiotics \[[@B19][@B20]\]. So those four newborns with positive mutations should avoid use of aminoglycoside antibiotics to avoid or postpone hearing loss. The mutation rates of two possible pathogenic mutations m.827A\>G and m.1005T\>C in mtDNA 12S rRNA was up to 3.3% and 3.6% respectively. The mutation rate of m.827A\>G in current study is much higher than that in which the m.827A\>G mutation rates are far higher than Brazil neonatal population (0.03%) \[[@B16]\]. The carrier rate of m.1005T\>C in 1642 children of Chinese Han people with nonsyndromic deafness was 0.61% \[[@B15]\]. None was reported about the carrier rate in the neonatal population. m.827A\>G and m.1005T\>C has been reported in AAID pedigrees from various ethnic groups, which showed that above mutations may not cause deafness, but plays an important role in the pathogenesis of AAID. Carriers with above two mutations also need to be informed to avoid the use of aminoglycoside antibiotic and regular follow-up. Carriers with four pathogenic mutations will be studied by family survey.

Some common deafness-associated mutations are associated with mild and/or progressive hearing loss. There will be false-negative results in some neonates with late-onset or mild hearing loss merely by NHS. A retrospective study on probands with deafness found that, up to 3.8%-8% of neonates who passed NHS contracted hearing loss caused by the mutation of *GJB2* gene \[[@B21][@B22]\]. Young et al. \[[@B23]\] reported that, among 108 cases who received the treatment of cochlear implantation, 32 cases (29.6%) had passed the examination of NHS before eight years. Which indicated there is a limitation of the NHS in recognition of patients with late-onset deafness. How to identify late-onset or progressing deafness in the baby or child earlier have been in the project of Early Hearing Detection and Intervention (<http://www.CDC.gov/NCBDDD/EHDI/nationalgoals.htm>), but there are not very effective method to achieve this goal. Some common *GJB2* mutations, such as p.M34T and p.V37I are associated with mild-to-moderate SNHI \[[@B24]\]. Previous studies indicated that mutation screening for *GJB2* deafness gene is valuable for judging, closely observed, and early detected for the baby with progressive or late-onset deafness with practicality, making these babies were closely observed, progress in the early detection of their deafness. Detection of m.1494C\>T and m.1555A\>G mutations in *SLC26A4* gene and mtDNA 12S rRNA was of greater significance for the outcome. For carriers with m.1494C\>T and m.1555A\>G mutations in mtDNA 12S rRNA, deafness causation is the greatest attraction of aminoglycoside \[[@B18]\], so such mutations carriers you want to absolutely avoid the use of aminoglycoside antibiotics. Aminoglycoside antibiotics widely used in China, the latest survey found that in 28% of 1,642 patients with whole hearing loss were induced by aminoglycoside drugs \[[@B15]\]. In other words, newborn genetic screening might be useful for identifying slight/mild hearing loss that was not detected by conventional NHS.

The project of implementation of neonatal screening for deafness genes is different for different neonates. Although the *GJB2* gene is considered to be the most common cause of hereditary deafness in most population of the world, the mutations rates are various in different races or in different regions. As to China c.235delC and p.V37I are common mutations \[[@B25]\]. The prevalence of EVA and DFNB4 caused by *SLC26A4* gene mutation and nonsyndromic *GJB2* gene mutation is the second followed by *GJB2* gene mutation \[[@B26]\], whose mutation types also differ in the different populations. p.T416P and c.1001+1G\>A are common mutations in Nordic population \[[@B27]\]; p.H723R is the most common form of mutant in Japan \[[@B26]\] and Korea \[[@B25]\] population. The most common mutation in Chinese population is IVS7-2A\>G, followed by p.H723R; but in patients with nonsyndromic deafness in Tibetan of China, carrier rate of *SLC26A4* mutation in *GJB2* gene is much lower than other region \[[@B28]\]. m.1555A\>G mutation in mtDNA 12S rRNA in deaf patients was reported all over the world, the mutation rate of m.1494C\>T mutation in Chinese patients with different phenotypic of sensorineural deafness is only 0.1%, much lower than that of m.1555A\>G (1.72%). In this study, the mutation rate of m.1494C\>T and m.1555A\>G are the same in newborns (both are 0.3%). Furthermore, besides the common c.235delC in Chinese population, the carrier rates of p.R143W is high in Jinan area. IVS7-2A\>G is the most common mutation in *SLC26A4* gene. It is thus clear that the screening program in different regions should be developed according to genetic testing results for people on the ground.

In short, neonatal screening for common deafness gene, can explores the causation of hearing impairment of newborns who failed the NHS on the molecular level, help us to find patients with mild hearing loss and aminoglycoside antibiotic-sensitive carriers, and provides early guidance to rationality of neonatal medicine, so as to effectively prevent or delay hearing loss. This research got the information on the local carries with mutations in the deafness gene, and laid a good foundation for promoting neonatal screening for deafness gene in the future.
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![Genotype mass spectra of mutational sites. (A) *GJB2* c.235delC heterozygous mutation; (B) *GJB2* p.R143W homozygous mutation; (C) *GJB3* p.V84I heterozygous mutation; (D) *GJB3* p.R180X heterozygous mutation; (E) *SLC26A4* IVS7-2A\>G heterozygous mutation; (F) *SLC26A4* p.R409H heterozygous mutation. *GJB2*, gap junction beta-2 protein; *GJB3*, gap junction beta-3 protein; *SLC26A4*, solute carrier family 26 member 4. a, wild type; b, mutant type.](ceo-8-211-g001){#F1}

###### The 20 common deafness mutational sites in current screening
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*GJB2*, gap junction beta-2 protein; *GJB3*, gap junction beta-3 protein; *SLC26A4*, solute carrier family 26 member 4; mtDNA, mitochondrial DNA.

###### Hearing screening results of 646 newborns
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OAE, otoacoustic emission; NHS, newborn hearing screening.

###### Gene screening results of 11 neonates who failed in newborn hearing screening
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*GJB2*, gap junction beta-2 protein; *GJB3*, gap junction beta-3 protein.

###### Gene screening and newborn hearing screening results of neonates with pathogenic mutations
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*GJB2*, gap junction beta-2 protein; *GJB3*, gap junction beta-3 protein; *SLC26A4*, solute carrier family 26 member 4.

###### Gene screening and newborn hearing screening results of neonates with suspected pathogenic mutations
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*GJB2*, gap junction beta-2 protein; *GJB3*, gap junction beta-3 protein.
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